The effect of the polymorphism in IL-28B gene on the treatment response of a combined therapy by sofosbuvir and daclatasvir with and without ribavirin in HCV Egyptian patients

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

Interleukin 28b Single Nucleotide Polymorphism (rs8099917) as a Predictive Factor of Response to Pegylated-IFN/Ribavirintherapy in Chronic HCV Patients

Predictors of Sustained Virological Response in Chronic Hepatitis C Patients Treated with Current Direct Acting Antiviral Drugs

Response to Hepatitis B Vaccine in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclat

Effect of Treatment of Hepatitis C by Directly Acting Antivirals (DAA) on Chronic Hepatitis C, B Coinfected Patients

Impact of Treatment of Chronic HCV Patients by Direct Acting Antiviral Drugs (DAADs) on COVID -19 Disease Frequency and Severity

INTERLEUKIN 28B GENE POLYMORPHISMS AS A PREDICTOR OF TREATMENT RESPONSE IN EGYPTIANS WITH CHRONIC HEPATITIS C.

Impact of Hepatitis C virus Infection and direct-acting Oral Antiviral Drugs on glycaemic state in Type 2 Diabetic Patients